Triumvira’s TAC01-CD19 Receives FDA’s Fast Track Designation for R/R Diffuse Large B-Cell Lymphoma

 Triumvira’s TAC01-CD19 Receives FDA’s Fast Track Designation for R/R Diffuse Large B-Cell Lymphoma

Triumvira’s TAC01-CD19 Receives FDA’s Fast Track Designation for R/R Diffuse Large B-Cell Lymphoma

Shots:

  • The US FDA has granted FT designation to Triumvira’s TAC01-CD19 for patients with relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL) prior treated with at least two systemic therapies
  • The TAC technology will significantly improve the limitation of existing cell therapies, including the risk of cytokine release syndrome and neurotoxicity, expanding treatment option for the patients
  • TAC01-CD19 is a novel T-cell therapy targeting CD19 with the expected onset of its P-I/II study (TACTIC-19) evaluating patients with CD19-positive B-cell malignancies, including DLBCL by the year-end 2019

Click here to­ read full press release/ article | Ref: Businesswire | Image: BusinessWire

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post